Additional Prognostic Value of Lymph Node Ratio (LNR) and Number of Negative Lymph Nodes (NLNs) in Chinese Patients with Triple Negative Breast Cancer
- PMID: 28249920
Additional Prognostic Value of Lymph Node Ratio (LNR) and Number of Negative Lymph Nodes (NLNs) in Chinese Patients with Triple Negative Breast Cancer
Abstract
Objective: This study aimed to investigate the prognostic value of lymph node ratio (LNR), number of removed lymph nodes (RLNs), and number of negative lymph nodes (NLNs) in Chinese patients with triple negative breast cancer.
Methods: The study cohort comprised 394 breast cancer patients with the triple negative subtype. The log-rank test and Cox proportional hazards analysis was employed to identify prognostic clinicopathological factors.
Results: The median follow-up time was 61 months, and the five-year disease-free survival (DFS) and overall survival (OS) were 63.75% and 64.97%, respectively. Univariate Cox survival analysis revealed that pN stage, LNR, and NLNs were significant prognostic factors for DFS and OS (all, p<0.05). Multivariate analysis including pN stage and LNR showed that LNR was an independent prognostic factor for DFS (p=0.047) and OS (p=0.0497). When combining pN stage, LNR, and NLNs together, only NLNs was an independent prognostic factor for DFS and OS (p=0.014). LNR is prognostically superior to pN stage in patients with triple negative breast cancer.
Conclusions: Our study revealed that LNR and NLNs can provide additional prognostic value for DFS and OS. Moreover, LNR had a better prognostic value compared with pN stage.
Keywords: Breast cancer; Lymph node ratio; Negative lymph node; Prognosis.
© 2017 by the Association of Clinical Scientists, Inc.
Similar articles
-
Number of negative lymph nodes should be considered for incorporation into staging for breast cancer.Am J Cancer Res. 2015 Jan 15;5(2):844-53. eCollection 2015. Am J Cancer Res. 2015. PMID: 25973321 Free PMC article.
-
The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.J BUON. 2015 May-Jun;20(3):737-45. J BUON. 2015. PMID: 26214625
-
Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.Asian Pac J Cancer Prev. 2013;14(9):5219-23. doi: 10.7314/apjcp.2013.14.9.5219. Asian Pac J Cancer Prev. 2013. PMID: 24175804
-
Impact of negative lymph node removal on survival in esophageal cancer: a systematic review and meta-analysis.BMC Surg. 2025 Mar 28;25(1):124. doi: 10.1186/s12893-025-02858-0. BMC Surg. 2025. PMID: 40155975 Free PMC article.
-
The prognostic value of lymph node ratio for thyroid cancer: a meta-analysis.Front Oncol. 2024 Feb 7;14:1333094. doi: 10.3389/fonc.2024.1333094. eCollection 2024. Front Oncol. 2024. PMID: 38384804 Free PMC article.
Cited by
-
Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System.Front Cell Dev Biol. 2022 Apr 4;10:784920. doi: 10.3389/fcell.2022.784920. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35445014 Free PMC article.
-
Metastatic lymph node ratio as a prognostic indicator in patients with stage IV colon cancer undergoing resection.J Cancer. 2019 Jun 2;10(11):2534-2540. doi: 10.7150/jca.29216. eCollection 2019. J Cancer. 2019. PMID: 31258759 Free PMC article.
-
An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients.Cancer Manag Res. 2018 Jun 18;10:1597-1604. doi: 10.2147/CMAR.S160100. eCollection 2018. Cancer Manag Res. 2018. PMID: 29950897 Free PMC article.
-
Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort.Ann Surg Oncol. 2022 Sep;29(9):5772-5781. doi: 10.1245/s10434-022-11911-8. Epub 2022 Jun 3. Ann Surg Oncol. 2022. PMID: 35661275 Free PMC article.
-
Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.Med Sci Monit. 2020 Apr 29;26:e922420. doi: 10.12659/MSM.922420. Med Sci Monit. 2020. PMID: 32348295 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources